Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 3Breast Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Osteoporosis 1Neuroblastoma 1Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Cystic Fibrosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Diseases 1Breast Carcinoma In Situ 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 86atezolizumab 80pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 44Radiofrequency Ablation 44Hepatectomy 43Leucovorin 41camrelizumab 40Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28Gemcitabine 26Cyclophosphamide 26cabozantinib 25Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Bone Density × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡